Previous Article | Next Article ![]()
Journal of Virology, September 2005, p. 11280-11290, Vol. 79, No. 17
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.17.11280-11290.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
,
Alberto López-Bueno,
and
José M. Almendral*
Centro de Biología Molecular "Severo Ochoa" (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), 28049 Cantoblanco, Madrid, Spain
Received 22 February 2005/ Accepted 14 June 2005
|
|
|---|
|
|
|---|
More-detailed information on the molecular determinants of the multiple factors involved in virus host range and pathogenicity is obtainable for genetically simple viruses. In the Parvoviridae, a family of nonenveloped icosahedral viruses with a 5-kb single-stranded DNA genome organized into two overlapping transcription units (19, 59), host range, tropism, and fitness determinants were mapped in the early promoter (21) and in the NS1 and NS2 nonstructural proteins (30, 49, 69, 82), though most determinants have been mapped to the capsid gene encoding the VP1 and VP2 structural proteins. For example, a region of the capsid gene determined the host range of porcine parvovirus (PPV) (7, 82), and a few residues of the VP2 protein influenced in vivo replication of the Aleutian mink disease virus (8, 27) or conferred the tropism of the canine parvovirus (CPV) toward canine and feline cells (37). Interestingly, specific recognition, at the cell surface, of the transferrin receptor dictates the host range of the CPV and feline parvovirus (FPV) in nature (36, 63) and underlies the emergence of new isolates during the rapid evolution of these viruses (75, 81).
The two best-characterized strains of the parvovirus Minute Virus of Mice (MVM), which show different tropism and pathogenicity characteristics even though they share 97% homology in their nucleotide sequences (3), comprise an interesting simple viral model to precisely define molecular bases of parvovirus virulence. The immunosuppressive strain (MVMi) was isolated from the EL-4(G-) lymphoma (10), whereas the prototype strain, parvovirus MVM (MVMp), was isolated from an adenovirus stock (20), grown in mouse embryo culture, and plaque purified in mouse fibroblasts without forced adaptive passages (reviewed in reference 86). In vitro, MVMp productively infects mouse fibroblasts such as the A9 cell line (19), and MVMi infects mouse T-lymphoid cell lines (57) and primary hemopoietic precursors (71). The tropism and host range determinants of MVMi and MVMp localized mainly in a region of the genome contained within the capsid gene (1, 16, 30) that for the acquisition of fibrotropism was mapped to a 237-nucleotide (nt) sequence called the "allotropic determinant" (30), of which two amino acid (residues 317 and 321) played the major role (5), via the VP2 major capsid protein (56). In the MVM capsid structure (2), these two VP2 residues localize nearby some of the important amino acids determining parvovirus CPV and PPV host range (33, 37, 82). In the nonpermissive cells the infection of the incoming MVM virion is restricted prior to transcription and gene expression (1, 29), though both virus strains compete for specific binding sites (79) which are highly abundant in permissive mouse fibroblasts (45). Therefore, it was suggested that the MVM strains use a common cell surface receptor for attachment and that target cell specificity would be mediated by the subsequent interaction of the allotropic determinant with unknown intracellular host factors (79), which may alter nuclear decapsidation or complete genome release (65).
At the organism level, the virulence of the MVM strains was studied at three developmental stages of the mouse host. (i) In intranasal inoculations of the newborn, MVMi induced a runting syndrome at a low viral dose (43) and a lethal infection in some inbred strains at a high dose with renal papillary hemorrhage and replication in endothelia (13), neuroblasts (66), and hemopoietic precursors (73), whereas MVMp infection was asymptomatic and the virus replicated at a low titer in several organs, with the exception of the high titers found in intestine (12). Significantly, a recombinant MVMp virus carrying the MVMi allotropic determinant caused a lethal infection of the newborn and replicated in the same target cells as MVMi (12). (ii) In the developing embryo, the MVM strains infected a broad set of cell types that partly overlapped but in which the tropism of MVMp for fibroblasts and of MVMi for endothelium, and the higher pathogenicity of MVMi, were conserved (42). (iii) In adult mice with severe combined immunodeficiency (SCID), MVMi infection led to an acute lethal leukopenia (74) and the suppression of long-term repopulating hemopoietic stem cells (72). The SCID mouse as a model to gain insights into hallmarks of MVMi biology has been recently validated in the natural selection of pathogenic mutants resistant to neutralizing anticapsid antibodies (48) and of viruses with increased fitness by enhanced NS2-mediated sequestration of the cellular CRM1 nuclear export receptor (49).
In this study, the MVM evolutionary potential was exploited for the analysis of parvovirus virulence through attempting the adaptation of MVMp to adult SCID mice. In this model of experimental evolution, we show that the apathogenic MVMp consistently evolves, after weeks of subclinical infection, to virulent variants that have acquired the capacity to cause a systemic lethal disease by the natural oronasal route. The virulent variants remained fibrotropics, in agreement with the lack of genetic changes in the main capsid determinant of MVM tropism. The viral emergence was not due to the access to a different receptor. Instead, the capsid of the virulent variants exhibited a lowered avidity for a primary receptor used in the MVMp productive infection. The study provides evidence for the crucial role that the tightness of capsid-receptor recognition plays in parvovirus virulence at the organism level, a new concept dramatically exemplified by the MVMp adaptation to SCID mice, in which the virus evolves from being asymptomatic to inducing a lethal disease.
|
|
|---|
The recombinant WT-VP3B virus was constructed by exchanging the Hind III-XbaI (nt 2650 to 4342) restriction fragment of pMM984 encompassing 89% of the coding sequence of the VP2 protein (3) for the corresponding fragment of the 3B virus genome, gel purified from restriction enzyme-digested DNA replicative intermediates that had been isolated from infected NB324K cells (57). The chimeric plasmid was transfected and amplified in the Escherichia coli strain JC8111 (9), and viral stocks were prepared and purified from electroporated NB324K cells following described methods (69). Except for the particular comparative assay shown (see Fig. 2), the virus titers in all the experiments described in this report were determined by a PFU assay on NB324K monolayers (80). The specific infectivity of the viral stocks prepared for MVMp and the isolated variants was close to 1 PFU/500 viral particles as determined by hemagglutination and VP protein staining (see below).
![]() View larger version (46K): [in a new window] |
FIG. 2. Features of the isolated MVMp variants in culture. (A) Plaque phenotype of MVMp and of the 3B and 5B virus variants in two fibroblast cell lines. Numbers are arbitrary units to designate the infectious titers (PFU) of the inocula. (B) Killing of mouse A9 cells. Monolayers of A9 cells were inoculated at 37°C with MVMp viruses at the indicated MOI normalized by a PFU assay in NB324K cells, and viable cells were determined as countable colonies 10 days afterwards. Represented is the average from five independent experiments. (C) Viral progression. Cultures of 3 x 105 A9 cells were inoculated at an MOI of 0.1, and the numbers of viable cells were counted by trypan blue exclusion as a function of time. The result is the average of two determinations. (D) Virus yield in a one-step growth assay. Cultures of highly synchronized A9 cells (19) were inoculated at an MOI of 20, and the total infectious virus levels were determined as PFU as a function of time. The figure shows the average of three independent experiments.
|
Monitoring viral multiplication in mice. Animals were euthanized and the excised organs washed in PBS, containing 0.9 mM CaCl2 and 0.5 mM MgCl2, weighed, and quick frozen in dry ice. The organs were diluted in PBS to a 10% wt/vol ratio and rapidly homogenized (UltraTurrax T25; IKA-Labortechnik). To determine infectious virus in the organs, homogenized samples centrifuged to remove debris were serially diluted in PBS and inoculated onto monolayers of NB324K cells for plaque assays. Viral DNA synthesis in mice was determined by low-molecular-weight DNA extraction (57) and Southern blotting as described previously (74). When indicated, the plaques arising from the organs were probed to determine whether they were of MVM origin. For this purpose, nitrocellulose lifts were taken at 6 days postinfection (dpi) from the monolayers and hybridized to an MVM DNA probe at high stringency.
For the determination of MVM viremia, a method was developed for efficient isolation of virions associated with circulating peripheral blood cells. Cells from 10 to 50 µl of blood obtained from the tail vein were washed three times in 1.5 ml of PBS and lysed by digestion with 0.2% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS) for 15 min at 37°C, and low-molecular-weight products were removed by spun-column chromatography (2,000 x g, 2 min) in Sephadex G-50-80. This procedure allowed 50 to 80% recoveries in the excluded fraction of infectious MVMp bound for 30 min at 37°C to mouse erythrocytes in control tests in vitro, while the freeze-thaw extraction cycles commonly used for infected cell lines yielded about 1% of the bound virus. Viral genomes in the excluded fraction equivalent to 1 µl of blood were extracted by Hirt's procedure (57) and measured by a semiquantitative PCR of 25 cycles with the oligonucleotides VVP6 (nt 3444 to 3460) and VPSEQO (nt 4706 to 4688) in a Perkin-Elmer DNA Cetus (Gene Amp PCR system 9600) or Bio-Rad gene cycler as described previously (48). The amplified 1.25-kbp DNA fragment was resolved by 1% agarose gel electrophoresis.
Cell lines and primary kidney cultures. The A9 mouse fibroblast cell line (a variant of mouse L cells) (46) and the NB324K simian virus 40-transformed human newborn kidney cell line (76), described as permissive hosts for the productive infection of MVM strains (80), were maintained with a minimal number of passages in Dulbecco's Modified Eagle Medium supplemented with 5% heat-inactivated fetal calf serum (Gibco BRL). When indicated, A9 cells were synchronized by isoleucine deprivation and aphidicolin treatment as described previously (19). To obtain primary epithelial cells from mouse kidneys, the method of culturing in D-valine as a selective agent (31, 50) was used. Kidneys were excised from 2- to 3-week-old SCID mice, the capsule was aseptically removed, and the organ was carefully minced and dispersed to cell suspensions by gentle treatment with a Dounce homogenizer and collagenase and seeded in dishes with MEM-D-Val selective medium (Gibco) supplemented with 15% fetal calf serum, and cultures were grown for 2 weeks before use.
The effect of one round of MVM infection on cell proliferative capacity was measured by a previously described clonogenic assay (17, 67) with minor modifications. Cell monolayers seeded at a density of 5,000 cells/cm2 the day before, or in suspension at a concentration of 105 cells/ml, were infected at increasing MOIs (0.2 to 100 PFU/cell) and plated at 4 h postinfection at various densities (2 x 102 to 2 x 104 cells per 60-mm-diameter dish) in triplicate to obtain a number of statistically representative cellular clones. Cells were incubated for 10 days in medium supplemented with a neutralizing dilution of an MVM capsid antiserum to block reinfections, and arising colonies were fixed in absolute methanol and stained with 1% crystal violet. Survival is expressed as the percentage of colonies in the infected versus the uninfected cultures normalized for the number of plated cells.
Binding assays. Cells detached from the plates by controlled trypsin digestion (A9) or EDTA treatment (primary epithelial kidney cells) were incubated for 30 min at 37°C in medium with serum to restore surface properties, washed with PBS three times, and incubated with [35S]methionine-cysteine radiolabeled MVM particles purified as described previously (52, 53). Typical binding assays were performed with 1 x 106 to 2 x 106/ml cells incubated with 15,000 cpm of 35S-labeled capsid in 100 µl of PBS at 4°C to minimize virus uptake into cells for the time indicated in the figure legends. Upon binding, cells were extensively washed in PBS to remove unbound capsids and centrifuged and the radioactivity associated with the cell pellets was determined by liquid scintillation counting. In the study of cytotoxic interactions of infectious particles to cells, 105/ml A9 cells in 150 µl of PBS were incubated with purified viruses (MOI of 100) at 4°C for the indicated time periods and cell survival was determined by a clonogenic assay as above.
The specificity of the attachment of labeled capsids and infectious virions to cells was probed by competing with graded amounts of unlabeled empty capsids. The specific activity of labeled capsids (1 x 105 to 3 x 105 cpm/µg) and the stoichiometry in the competitions were carefully adjusted for each experiment by measuring the number of particles by VP protein staining with Coomassie blue in 10% SDS-polyacrylamide gel electrophoresis, using bovine serum albumin protein (Sigma) as the standard, and values were further validated in standard hemagglutination with mouse erythrocytes. Wild-type (wt) and MVMp variant capsids showed similar levels of hemagglutination activity (2 h at 4°C), with titers in the range of 2 x 103 to 6 x 103 hemagglutination units/µg of VP protein.
|
|
|---|
![]() View larger version (32K): [in a new window] |
FIG. 1. Emergence of MVMp variants in SCID mice. (A) Infectious titers in three major organs of SCID mice inoculated intravenously with MVMp (107 PFU/mouse), as determined by plaque assay in the NB324K cell line. The mean values and standard deviation from at least three mice per point from two independent inoculations are shown. DL, detection limit of the assay (250 PFU/g of wet tissue). (B) Examples of the heterogeneous plaque size distribution of MVMp variants harvested from mouse organs at two postinfection times. (C) Plaques of all sizes hybridize to a 32P-labeled DNA probe of MVM genome after overnight exposure.
|
|
View this table: [in a new window] |
TABLE 1. Plaque phenotype of MVMp variants isolated from SCID mice
|
Virulent MVMp variants emerge in SCID mice. To investigate whether the different plaque phenotypes reflect a pertinent biological property, the capacity of the 3B and 5B variants to spread and multiply in three major organs was monitored following reinoculation into SCID mice. The infectious titer of the 5B variant inoculated intravenously (Fig. 3A, right panel) remained at low levels (kidney and liver) or below the detectable level (brain) in these mouse organs up to 12 wpi. In sharp contrast, the presence of the 3B variant was demonstrable at moderate infectious titer in all three organs by 2 wpi, and the titer increased by several orders of magnitude within a few weeks (Fig. 3A, left panel). Consistent with this observation, the accumulation of viral DNA replicative intermediates analyzed at 9 wpi was high in the liver of 3B inoculated mice, moderate in the kidney, and low in the brain, whereas 5B replicative forms were undetectable by conventional Southern blotting in any of the organs (Fig. 3A, middle panel). These analyses probed the capacity of the 3B virus to multiply in mouse organs.
![]() View larger version (31K): [in a new window] |
FIG. 3. Virulence of isolated MVMp variants in SCID mice. (A) Multiplication of two MVMp variants reinoculated in SCID mice. The figure shows the infectious titers in the organs of SCID mice at the indicated times postintravenous inoculation (107 PFU/mouse) with the 3B and 5B variants. Upper right panel: Southern blot of low-molecular-weight DNA extracted from mouse organs, by the Hirt procedure, at 9 wpi and hybridized with a 32P-labeled MVM probe. DNA extracted from 5 mg of organ was loaded per gel slot, and membranes were exposed for 40 h for autoradiography. B, brain; K, kidney; L, liver; r, replicative intermediate markers. The positions of the dimer replicative form (dRF) and monomeric replicative form (mRF) are indicated. (B) Infectious titers in major organs of SCID mice oronasally inoculated (107 PFU/mouse) with the indicated purified viruses. The data for the wt and 5B viruses were obtained at 12 wpi and for the rest of variants at 8 wpi. Values are the mean and standard deviation for at least 3 mice per point from two independent inoculations. DL, detection limit of the assay.
|
The capsid of virulent variants binds with lower affinity than MVMp to the receptor used for the cytotoxic infection. In the absence of molecular data accounting for virulence and plaque formation, the slightly different slopes of A9 killing (Fig. 2B and C) suggested that the initial virus-cell interaction might be altered in the isolated MVMp variants. We investigated this possibility by analyzing features of the virus-cell interaction at 4°C to avoid postbinding effects. As the expression of the cytotoxic NS1 nonstructural protein (15, 69) is a reliable test for the onset of MVM productive infection, the kinetics of cell interaction leading to the cytotoxic infection of representative MVMp variants was examined first. As shown in Fig. 4A, the survival curves of A9 cells indicated a rapid binding of the MVMp and 5B variant, as most infectious virus was bound by 15 min. In contrast, the 3B and the other large-plaque variants tested (4L, 4B, 2L, and 1B) interacted, without exception, with a much lower kinetics, as only about 50% of the cells were killed after 30 min of interaction. These characteristic cytotoxic interactions indicated a distinctly lower avidity of the MVMp variants for A9 cells.
![]() View larger version (21K): [in a new window] |
FIG. 4. Capsid affinity of MVMp variants to a primary fibroblast receptor. (A) Kinetics of cytotoxic interaction of MVMp variants to A9 cells. Purified viruses (MOI of 100) were allowed to bind at 4°C to A9 cells in suspension for the indicated time periods, and levels of surviving cells were determined by clonogenic assays. Representative results from at least two independent experiments are shown as percentage of survival with respect to the plating efficiency of the mock-infected cells. (B) MVMp and virus variants compete for A9 binding. 35S-labeled MVMp (blank symbols) or 3B (filled symbols) capsids were allowed to bind for 1 h at 4°C in the presence of competitor unlabeled MVMp (circles), 3B (squares), or 5B (triangles) capsids. Represented is the percentage of 35S radioactivity bound to cells (100% binding was approximately 3,000 cpm). (C) The 3B virulent variant shares receptor with MVMp for A9 infection. MVMp (blank symbols) or 3B (filled symbols) infectious viruses binding to A9 cells (MOI 100) for 1 h at 4°C were incubated with the indicated ratios of purified competitor MVMp (circles) or 3B (squares) capsids, and levels of surviving cells were determined by a clonogenic assay. The result is the average from three independent determinations.
|
To determine whether the different binding affinities are to a nonproductive attachment factor or involve the receptor used in the MVMp infection, the cytotoxic interaction of wt and 3B viruses was competed with increasing amounts of the respective homologous and heterologous empty capsids. According to the number of surviving viable cells shown in Fig. 4C, the infection of the 3B variant was completely competed by the wt capsid by use of a particle ratio of 102-fold excess, but a similar level of competition of the MVMp infection by the homologous capsid required at least a 103-fold excess. Instead, the 3B capsid significantly competed the infection of the homologous 3B virus only at very high particle ratios, close to 104-fold excess, and moreover its capacity to compete out the MVMp infection was poor at even the highest particle ratio. These data, which are consistent with the binding affinities shown in Fig. 4B, led us to conclude that MVMp and the 3B virulent variant use the same primary receptor to initiate the cytotoxic infection of A9 fibroblasts but that the interaction of 3B with this receptor occurs with lower affinity.
The VP gene determines MVMp plaque morphology, affinity of capsid-receptor interaction, and virulence in SCID mice. To study the genetic relationship between capsid affinity and virulence in mice, a chimeric genome was constructed, replacing most coding sequence of the VP gene in the MVMp wt genome with the equivalent region of the 3B genome (see Materials and Methods), and the phenotypic properties of the resulting recombinant virus (named WT-VP3B) were studied in vitro and in vivo. The plaque-forming capacity of the recombinant virus in A9 and NB324K cells was similar to that of the parental 3B variant, namely, large plaques in NB324K (2.6 ± 0.6 mm) and around a 1,000-fold higher NB324K/A9 ratio (not shown). As found for large-plaque variants, the plaque phenotype of the WT-VP3B recombinant virus correlated with slower kinetics in the cytotoxic interaction with A9 cells (Fig. 4A). These experiments suggested that the affinity of the capsid for the receptor is a major factor in MVMp plaque phenotype.
The virulence of the MVMp-VP3B virus in comparison with the wt was determined by the oronasal route in SCID mice. Consistent with the experiments shown in Fig. 3B, the titer of wt infectious virus in the major organs remained below detectable levels up to 8 wpi (Fig. 5A). In contrast, infectious WT-VP3B virus was recovered from the liver of some animals as early as 3 wpi and from the three organs in all the animals by 8 wpi (Fig. 5A) at titers slightly lower than, but paralleling, the results obtained for the parental 3B variant. As described above for MVMp, the WT-VP3B infection was not associated with the leukopenic syndrome induced by the MVMi strain since 6 wpi in SCID mice (74). These results indicate that the 3B capsid facilitates systemic infection from the oronasal route.
![]() View larger version (16K): [in a new window] |
FIG. 5. The MVMp-derived recombinant WT-VP3B virus is virulent when inoculated by the oronasal route. (A) Virus titers in organs of adult SCID mice after intranasal inoculation with purified recombinant WT-VP3B (107 PFU/mouse) or the wt strain (108 PFU/mouse). Each point corresponds to the infectious titer found in the organ of one individual mouse (n = 12 per virus). DL, detection limit of the assay. (B) Lethality of recombinant and variant MVMp viruses in SCID mice. Adult SCID mice were inoculated by the oronasal route with 107 PFU/mouse of purified WT-VP3B (n = 5), 3B (n = 10), or 5B (n = 10) viruses or with 108 PFU/mouse of the wt MVMp (n = 6) and scored for survival for 30 weeks.
|
In an attempt to localize the amino acid residues involved in MVMp virulence in SCID, the nucleotide sequence of a region of MVM genome (nt 3450 to 3800), corresponding to the amino acid residues 220 to 335 of VP2 (3), was determined in the entire collection of isolated MVMp variants (Fig. 3B and Table 1). This region encompasses the allotropic determinant governing the tropism of MVM strains (1, 5, 16, 30), as well as other main VP residues controlling CPV or PPV host range (7, 33, 37, 82) and adaptation in culture (4). DNA isolated from the respective viral stocks by a modified Hirt's procedure (57) was amplified by PCR and sequenced following a previously described methodology (48). None of the virus isolates, regardless of phenotypic features and virulence, showed any nucleotide change with respect to the updated reported sequence of the wild-type MVMp genome (reference 5 and data not shown). Thus, we had to conclude that the genetic basis of MVMp virulence in SCID is not directly related to the tropism determinants of MVM and other evolutionary close parvoviruses.
Analysis of MVMp attenuation in SCID mice: viremia and interaction with primary cells. To study, at the organism level, the basis of the virulence gained by the WT-VP3B virus with respect to the attenuated wt, the capacities of both viruses to cause viremia during natural infection were compared. Blood samples were collected from the tail vein at several dpi from two oronasally inoculated adult SCID mice per virus (108 PFU/mouse) and monitored for MVM viremia. As previously reported (34), MVM viruses were found associated with blood cells and not in the plasma fraction, and they could be efficiently recovered by an SDS-based extraction method and the number of genomes was estimated by semiquantitative PCR (see Materials and Methods). Blood samples collected from mice prior to virus inoculations were negative for MVM sequences (Fig. 6), but DNA of the WT-VP3B, as well as that of the MVMp viruses, was consistently demonstrated at similar genomic copy numbers (lower than 103/µl) in the cellular fraction of the blood at 1 to 2 dpi. However, a major difference between the two viruses was evident from their rate of clearance from the circulation, as the level of MVMp genomes in blood had dropped by 13 dpi and became barely detectable by 56 dpi in the two analyzed mice (SCID-1 and SCID-2), whereas the number of WT-VP3B genomes increased at 13 dpi and either declined (SCID-3) or increased to a titer higher than 104/µl (SCID-4) at 56 dpi. Parallel studies in vitro suggested that MVMp clearance was not due to inactivation or irreversible binding to mouse erythrocytes, as a similar proportion of wt and recombinant infectious virus, bound to erythrocytes, could be harvested by the SDS treatment mentioned above; moreover, 1 to 5% of 104 PFU of either viruses, bound to 107 erythrocytes, spontaneously released and formed plaques on NB324K cell monolayers (2.5 x 105 cells) after a 1-h incubation (not shown). These studies showed that both viruses invade the bloodstream by the oronasal route, where they remained presumably infectious, but the attenuated MVMp was cleared from circulation within a few dpi, whereas the accumulation of the WT-VP3B virus continued over many weeks, corresponding to its multiplication during this time in major organs of the host mouse (Fig. 5A).
![]() View larger version (29K): [in a new window] |
FIG. 6. Viremia and clearance of the MVMp and WT-VP3B viruses in SCID mice. Genomic copy numbers of the MVMp and WT-VP3B viruses in blood cells obtained from two oronasally inoculated SCID mice (108 PFU/mouse) at the indicated dpi. Low-molecular-weight DNA isolated from an equivalent of 1 µl of blood cells was subjected to semiquantitative PCR amplification of a 1.25-kbp region of MVM genome and loaded in 1% agarose gel. PCR amplification of measured numbers of viral particles (determined by hemagglutination) from the purified viral stocks used to inoculate the mice is shown in the left lanes.
|
![]() View larger version (19K): [in a new window] |
FIG. 7. Competitive binding of MVMp and 3B capsids to primary cells. The figure shows the specific interaction of 35S-labeled MVMp (wt) and 3B purified capsids to primary epithelial cells isolated from SCID kidney. Values are represented as the percentage of cell-bound radioactivity not competed off by the indicated excess of nonlabeled wt capsid (100% is about 2,000 cpm). The result is (with one exception) the average of three independent determinations, and standard errors are shown.
|
|
|
|---|
Emergence of MVMp variants in SCID mice. The course of MVMp multiplication in intravenously inoculated SCID mice developed with a characteristic rise in infectious titers in the mouse organs since 7 wpi (Fig. 1) and the absence of pathological signs for several weeks postinfection. This pattern is in sharp contrast to the severe leukopenic syndrome found in infections with the virulent MVMi strain by 6 wpi (74), consistent with the lack of MVMp tropism toward lymphohemopoietic cells (71). Unlike MVMi, the emerging variants conserved fibrotropism (Fig. 2) and did not show genetic changes in the allotropic determinant of the capsid (see Results) that contains 10% of the single-nucleotide differences between MVMi and MVMp (3, 5), suggesting that the acquisition of virulence is not due to gaining tropism for hemopoietic cells. Experiments are currently under way to identify the primary cells targeted by MVMp in adult SCID mice.
These virus variants arising in the organs showed, however, an altered plaque phenotype with respect to MVMp, as they formed large plaques in human cells but failed to efficiently plaque in A9 mouse fibroblasts (Table 1). The MVM plaque phenotype may be altered by several determinants of the VP (5, 53) and NS (49, 69) genes, acting at distinct life cycle steps. Here, the virus cycle of large-plaque variants did not show however any major different with respect to the MVMp other than a lower avidity in the primary interaction leading to A9 cell killing (Fig. 2). Furthermore, this interaction could be completely competed by wt capsids (Fig. 4), indicating that the receptor usage by the emerging MVM variants is within the receptor repertoire used by MVMp for A9 infection. However, whether the higher affinity of the MVMp capsid to cells is due to the access to additional binding sites that are not competed for by virulent capsids remains unexplored. Thus, it is likely that the lower avidity of the variant capsids for the A9 cell surface, which also occurs in NB324K cells (to be described elsewhere), facilitates their spreading in monolayers. This may account for the larger plaques in NB324K cells, whereas a less extensive A9 cell lysis (Fig. 2B) would result in diffused plaques not evident by eye inspection.
The adaptation of MVMp to SCID mice was consistently associated with gain of virulence. The emergence of variants showing a dramatic increase in virulence in reinoculated SCID mice indicated that MVMp genetically changed in the mice (Fig. 3). Given the altered binding to cells of the variant capsids, the analysis of virulence was focused in the capsid gene, a region of parvovirus genome where otherwise most determinants of host range and tropism have been mapped (see the introduction). The phenotypic analysis of the WT-VP3B recombinant virus, carrying the VP gene of the 3B virulent variant in the MVMp background, demonstrated that the large-plaque morphology, low affinity of receptor interaction, and intranasal virulence are indeed determined by the capsid gene (Fig. 5). The lack of genetic changes in the VP allotropic determinant sequenced in eight virus isolates (Table 1), together with the high genetic heterogeneity of the MVMi populations replicating in SCID mice (48, 49), indicate that a comprehensive sequence analysis of a large collection of MVMp variants will be required to understand the genetic basis of virulence.
Capsid affinity for the receptor in parvovirus pathogenesis. The basis of the strikingly different pathogenicity of MVMp versus the isolated virulent variants harboring capsids with low receptor affinity was analyzed at several levels. Mice oronasally inoculated by either MVMp or virulent variants become viremic with similar viral genome copy numbers by 1 to 2 dpi (Fig. 6), indicating that MVMp is not trapped during passage through the respiratory or gastrointestinal route of entry. Moreover, the virus remained infectious and bound to blood cells in vitro and therefore could access target tissues by hematogeneous spreading. In the interaction with primary epithelial kidney cells (Fig. 7), both viruses bound similarly and could be competed with wt capsids, suggesting that, as probed for the A9 mouse fibroblast cell line (Fig. 4B and C), the virulent variants do not access alternative receptors in this target organ. Thus, unlike most viral systems analyzed to date, the virulence in the MVMp-SCID model may not rely on extended receptor usage.
A comprehensive understanding of the connection between the affinity of capsid receptor interaction and MVMp pathogenesis deserves further research. In mouse infections by polyomavirus strains with different levels of pathogenicity (6), a weak interaction with the receptor appeared to facilitate spreading to distal host-susceptible organs, while high-affinity binding retained the nonpathogenic strains within nearby cells, limiting systemic infection. Analogously, in the MVMp-SCID model addressed here, in which virulent variants naturally emerged in an adult mouse host, this hypothesis would imply that the high-affinity binding of the MVMp apathogenic strain to cell sites not competed by the virulent capsids involves nonproductive receptors. Our study indicates, however, that the MVMp reached the bloodstream, where it remained infectious and bound to circulating cells (see above), confining this hypothetical restriction to postviremia interactions.
As an alternative hypothesis, the affinity of recognition of a common receptor by MVMp and the virulent variants in cells of target mouse tissues may be crucial for the initiation of a productive MVM infection. Viruses enter animal cells through complex entry and uncoating programs (78), and, as exemplified for the fusion step in influenza virus (60), the affinity of binding to the receptor may modulate multiple events required for infection. The entry of the genetically simpler members of the Parvoviridae is also a complex and only partly understood process (reviewed in reference 83) involving structural transitions of a metastable capsid to specifically externalize the VP N-terminal sequences at the virion surface (18, 47, 53, 68, 84). It is therefore conceivable that the number and tightness of parvovirus-receptor binding sites affect the capsid configuration at precise subcellular compartments, modulating overall the efficiency of nuclear invasion by the virus genome. In this sense, it may be worth evaluating the concept of differential affinity of the capsid for cell-surface receptors in other parvovirus infections, particularly in the hypothetical involvement of postattachment host factors determining MVMp/MVMi target cell specificity (29, 65, 79) and cell permissiveness to PPV infections (61), and in a pathogenic role of the recognition by CPV/feline parvovirus host range variants of the transferrin receptors (36, 38).
In a number of viral systems, alterations in the recognition of sugars as attachment receptors have been shown to modulate infection and pathogenicity (see, e.g., references 6, 14, 39, 51, 55, 64, 70, and 77). Interestingly, the sensitivity of the infection to enzymes suggested that the sialic part of a surface glycoprotein acts as an MVM receptor in permissive cells (19), and thus the interaction of the viral capsid with this receptor component could modulate the pathways of MVMp infection as hypothesized above. Experiments are under way in this laboratory to address this and other complex issues of MVMp pathogenesis, such as the identification of the host cells in mouse tissues targeted during MVMp replication and evolution, the nature of the primary receptor, and the genetic basis of the virulence.
In summary, this report demonstrates that a change of capsid affinity for the receptor is a major mechanism in the natural selection of virulent viruses in a single immunodeficient mammalian host. Two further conclusions, with potential general interest, could be drawn from this study. (i) Antiviral therapies targeting virus-receptor interactions must be undertaken cautiously, as they may favor severe systemic spreading of otherwise local infections or the selection of virus escape mutants with increased pathogenicity. (ii) The development of gene therapy protocols in which a hematogeneous systemic treatment with the viral vectors is desired might more usefully employ viral coats of low receptor affinity. The SCID mouse may constitute a suitable mammalian model for this kind of trial, since it allows the isolation of virus mutants useful in characterizing long-term pathogenic factors (references 48 and 49 and references therein).
This work was supported by grant SAF 2001-1325 CICYT from the Spanish Ministry of Science, by EU-Contract QLK3-CT-2001-01010, by grant 07B/0020/2002 from the Comunidad de Madrid, and by an institutional grant from Fundación Ramón Areces to the Centro de Biología Molecular "Severo Ochoa."
Present address: Instituto de Biomedicina de Valencia (CSIC), Valencia, Spain. ![]()
M.-P.R. and A.L.-B. contributed equally to this work. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»